Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Hainaut

Showing results (191-200 of 280) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
Lung squamous cell carcinomas with basaloid histology represent a specific molecular entityChristian Brambilla, Julien Laffaire, Sylvie Lantuejoul, et al.
Plos One|June 8, 2012
Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosisStephanie Villar, Sandra Ortiz-Cuaran, Behnoush Abedi-Ardekani, et al.
Oncotarget|March 16, 2018
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinomaZuzana Macek Jilkova, Ayca Zeybek Kuyucu, Keerthi Kurma, et al.
Nucleic Acids Research|October 2, 2007
Subcellular distribution of human RDM1 protein isoforms and their nucleolar accumulation in response to heat shock and proteotoxic stressLydia Messaoudi, Yun-Gui Yang, Aiko Kinomura, et al.
BMC Cancer|April 11, 2013
TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patientJuliana Giacomazzi, Simone Selistre, Juliana Duarte, et al.
Molecular Oncology|February 6, 2014
Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancerXiaoli Ma, Vanessa Rousseau, Haiji Sun, et al.
Breast (Edinburgh, Scotland)|March 16, 2013
Breast cancer in pre-menopausal women in West Africa: analysis of temporal trends and evaluation of risk factors associated with reproductive lifeDominique Sighoko, Bakarou Kamaté, Cheick Traore, et al.
The Journal of General Virology|November 25, 2011
Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cellsMyriam Lereau, Doriane Gouas, Stéphanie Villar, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 21, 2005
Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometryMatilde E Lleonart, Gregory D Kirk, Stephanie Villar, et al.
Carcinogenesis|July 5, 2012
TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The GambiaDoriane A Gouas, Stphanie Villar, Sandra Ortiz-Cuaran, et al.
Pageof 28

Showing results (191-200 of 280) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
Lung squamous cell carcinomas with basaloid histology represent a specific molecular entityChristian Brambilla, Julien Laffaire, Sylvie Lantuejoul, et al.
Plos One|June 8, 2012
Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosisStephanie Villar, Sandra Ortiz-Cuaran, Behnoush Abedi-Ardekani, et al.
Oncotarget|March 16, 2018
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinomaZuzana Macek Jilkova, Ayca Zeybek Kuyucu, Keerthi Kurma, et al.
Nucleic Acids Research|October 2, 2007
Subcellular distribution of human RDM1 protein isoforms and their nucleolar accumulation in response to heat shock and proteotoxic stressLydia Messaoudi, Yun-Gui Yang, Aiko Kinomura, et al.
BMC Cancer|April 11, 2013
TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patientJuliana Giacomazzi, Simone Selistre, Juliana Duarte, et al.
Molecular Oncology|February 6, 2014
Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancerXiaoli Ma, Vanessa Rousseau, Haiji Sun, et al.
Breast (Edinburgh, Scotland)|March 16, 2013
Breast cancer in pre-menopausal women in West Africa: analysis of temporal trends and evaluation of risk factors associated with reproductive lifeDominique Sighoko, Bakarou Kamaté, Cheick Traore, et al.
The Journal of General Virology|November 25, 2011
Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cellsMyriam Lereau, Doriane Gouas, Stéphanie Villar, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 21, 2005
Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometryMatilde E Lleonart, Gregory D Kirk, Stephanie Villar, et al.
Carcinogenesis|July 5, 2012
TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The GambiaDoriane A Gouas, Stphanie Villar, Sandra Ortiz-Cuaran, et al.
Pageof 28